The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta

被引：21

作者：

Rice, G ^{[1
]}

机构：

[1] Univ Western Ontario, Multiple Sclerosis Clin, London, ON N6A 5A5, Canada

来源：

ARCHIVES OF NEUROLOGY | 2001年 / 58卷 / 08期

关键词：

D O I：

10.1001/archneur.58.8.1297

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：1297 / 1298

页数：2

共 16 条

[1] DEVELOPMENT OF NEUTRALIZING AND BINDING-ANTIBODIES TO INTERFERON (IFN) IN PATIENTS UNDERGOING IFN THERAPY [J].

ANTONELLI, G .

ANTIVIRAL RESEARCH, 1994, 24 (2-3) :235-244

[2] Interferon β neutralizing antibodies in multiple sclerosis:: neutralizing activity and cross-reactivity with three different preparations [J].

Bertolotto, A ;

Malucchi, S ;

Milano, E ;

Castello, A ;

Capobianco, M ;

Mutani, R .

IMMUNOPHARMACOLOGY, 2000, 48 (02) :95-100

[3]

DELSENHAMMER F, 2000, NEUROLOGY, V54, P2055

[4]

DUQUETTE P, 1995, NEUROLOGY, V45, P1277

[5]

Duquette P, 1996, NEUROLOGY, V47, P889

[6] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis [J].

Ebers, GC ;

Rice, G ;

Lesaux, J ;

Paty, D ;

Oger, J ;

Li, DKB ;

Beall, S ;

Devonshire, V ;

Hashimoto, S ;

Hooge, J ;

Kastrukoff, L ;

Krieger, C ;

Mezei, M ;

Seland, P ;

Vorobeychi, G ;

Morrison, W ;

Nelson, J ;

Freedman, MS ;

Chrisie, S ;

Nelson, R ;

Rabinovitch, H ;

Freedman, C ;

Hartung, HP ;

Rieckmann, P ;

Archelos, J ;

Jung, S ;

Weilbach, F ;

Flachenecke, P ;

Sauer, J ;

Hommes, O ;

Jongen, P ;

Brouwer, S ;

McLeod, J ;

Pollard, J ;

Ng, R ;

Sandberg-Wollheim, M ;

Källén, K ;

Nilsson, P ;

Ekberg, R ;

Lundgren, A ;

Jadbäck, G ;

Wikström, J ;

Multanen, J ;

Valjakka, M ;

Carton, H ;

Lissoir, F ;

Declerq, I ;

Vieren, M ;

Peeters, E ;

Dubois, B .

LANCET, 1998, 352 (9139) :1498-1504

[7] Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. [J].

Jacobs, LD ;

Beck, RW ;

Simon, JH ;

Kinkel, RP ;

Brownscheidle, CM ;

Murray, TJ ;

Simonian, NA ;

Slasor, PJ ;

Sandrock, AW .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (13) :898-904

[8] Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis [J].

Jacobs, LD ;

Cookfair, DL ;

Rudick, RA ;

Herndon, RM ;

Richert, JR ;

Salazar, AM ;

Fischer, JS ;

Goodkin, DE ;

Granger, CV ;

Simon, JH ;

Alam, JJ ;

Bartoszak, DM ;

Bourdette, DN ;

Braiman, J ;

Brownscheidle, CM ;

Coats, ME ;

Cohan, SL ;

Dougherty, DS ;

Kinkel, RP ;

Mass, MK ;

Munschauer, FE ;

Priore, RL ;

Pullicino, PM ;

Scherokman, BJ ;

WeinstockGuttman, B ;

Whitman, RH ;

Baird, WC ;

Fillmore, M ;

Bona, LM ;

ColonRuiz, ME ;

Nadine, BS ;

Donovan, A ;

Bennett, S ;

Kieffer, YM ;

Umhauer, MA ;

Miller, CE ;

Kilic, AK ;

Sargent, EL ;

Schachter, M ;

Shucard, DW ;

Weider, V ;

Catalano, BA ;

Cervi, JM ;

Czekay, C ;

Farrell, JL ;

Filippini, JS ;

Matyas, RC ;

Michienzi, KE ;

Ito, M ;

OMalley, JA .

ANNALS OF NEUROLOGY, 1996, 39 (03) :285-294

[9]

PACHNER AR, 1997, NEUROLOGY, V49, P467

[10] Guidelines for physicians with patients on IFN beta-1b: The use of an assay for neutralizing antibodies (NAB) [J].

Paty, DW ;

Goodkin, D ;

Thompson, A ;

Rice, G .

NEUROLOGY, 1996, 47 (04) :865-866

← 1 2 →